drugset / Trial / NCT05003752
Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Hypo-Combi Trial: A Prospective Phase I/II Study of Combined Hypofractionated External Beam Radiation Therapy (EBRT) plus Interstitial High-Dose-Rate Brachytherapy (HDR-BT) for Intermediate/High Risk Prostate Cancer
Timeline
- Start
- 2021-08-01
- Primary completion
- 2022-12-31
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Goserelin | Other / unclassified | 10.8 mg | — |